At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Skin disorders
Most Recent Events
- 15 Jul 1998 Profile reviewed
- 15 Jul 1998 No-Development-Reported for Skin disorders in Switzerland (Unknown route)
- 15 Jul 1998 No-Development-Reported for Skin disorders in Austria (Unknown route)